Medicine and Dentistry
Prostate Cancer
100%
Robot-Assisted Prostatectomy
70%
Partial Nephrectomy
51%
Cystectomy
50%
Neoplasm
41%
Molecularly Targeted Therapy
39%
Gamma Urogastrone
39%
Continence
36%
Transitional Cell Carcinoma
34%
Prognostic Factor
32%
Lactate Dehydrogenase
29%
Gleason Score
29%
Urinary Diversion
28%
Lymph Node Metastasis
25%
Bladder
25%
Bleeding
24%
Survival Rate
22%
Invasive Bladder Cancer
22%
Neoadjuvant Chemotherapy
22%
Prostate Biopsy
22%
Urinary System
21%
Postoperative Ileus
20%
Primary Tumor
20%
Ureter
19%
Retrospective Study
19%
Gene Amplification
19%
Fluorescence in Situ Hybridization
19%
Cyclooxygenase 2
19%
Bone Metastasis
19%
Retroperitoneal Lymph Node Dissection
19%
Prothrombin
19%
Chromogranin A
19%
Extracorporeal
19%
Epidermal Growth Factor Receptor 2
19%
Recurrent Disease
17%
Ileal Conduit
17%
Biopsy
17%
Computer Assisted Tomography
17%
Overall Survival
17%
Needle Biopsy
16%
Cause Specific Survival
16%
Cancer Specific Survival
15%
Urine Incontinence
15%
Cell Differentiation
14%
Disease
13%
Prostate Specific Antigen
13%
Nephroureterectomy
13%
Kidney Tumour
13%
Bladder Cancer
12%
Radical Nephrectomy
12%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
59%
Gamma Urogastrone
39%
Pharmacodynamics
39%
Prostatitis
39%
Transitional Cell Carcinoma
36%
Bladder Cancer
32%
Pharmacokinetics
29%
Lymph Node Metastasis
29%
Primary Tumor
21%
Renal Cell Carcinoma
20%
Survival Rate
20%
Lactate Dehydrogenase
19%
Bone Metastasis
19%
Cyclooxygenase 2
19%
Epidermal Growth Factor Receptor 2
19%
Prothrombin
19%
Chemotherapy
19%
Gleason Score
19%
Drug Concentration
19%
Minimum Inhibitory Concentration
17%
Kidney Metastasis
16%
Neoplasm
16%
Cause Specific Survival
14%
Malignant Neoplasm
12%
Immunotherapy
11%
Recurrence Risk
11%
Sunitinib
9%
Androgen Receptor
9%
Tryptophan 2,3 Dioxygenase
9%
Chromogranin A
9%
Piperacillin Plus Tazobactam
9%
Heat Shock Protein 27
9%
Muscle Invasive Bladder Cancer
9%
Docetaxel
9%
Pazufloxacin
9%
Meropenem
9%
Racemase
9%
Clinical Pharmacokinetics
9%
Adverse Event
9%
Biochemical Recurrence
9%
Doripenem
9%
Ureter Stone
9%
Circulating Tumor DNA
9%
Hyperthermia
9%
Bladder Carcinoma
9%
Aptamer
9%
Prostate Hypertrophy
9%
Antibacterial Activity
9%
Disease
8%
Prostate Specific Antigen
8%
Keyphrases
Bladder Transitional Cell Carcinoma
20%
Molecular Targeted Therapy
19%
Cyclooxygenase-2
19%
Robot-assisted Radical Prostatectomy
19%
Human Epidermal Growth Factor Receptor 2 (HER2)
19%
Invasive Bladder Cancer
13%
Survival Rate
10%
Cyclooxygenase-2 Expression
10%
Secondary Bladder Cancer
9%
Risk Factors
9%
Gleason Score
9%
Lactate Dehydrogenase
9%
Tumor Extent
9%
Solitary Brain Metastasis
9%
Gene Amplification
9%
Renal Carcinoid
9%
Deep Ensemble
9%
Castration Resistance
9%
Pharmacodynamics Target Attainment
9%
Growth Resistance
9%
Fluorescence in Situ Hybridization
9%
Robot-assisted Radical Nephrectomy
9%
High-grade Prostate Cancer
9%
Pharmacodynamic Evaluation
9%
Clinical Data
9%
Ensemble Machine Learning
9%
Prostate Cancer Patients
9%
Nerve Sparing
9%
Inferior Vena Cava Thrombectomy
9%
Pentafecta Outcomes
9%
Intracorporeal Ileal Conduit
9%
Bone Metastasis
9%
Castration-resistant Prostate Cancer Cells
9%
Functional Peptides
9%
Stripping Technique
9%
Resistance to Immunotherapy
9%
Urethral Suspension
9%
Intraoperative Navigation
9%
High Complexity
9%
Selective Clamping
9%
Laparoscopic Retroperitoneal Lymph Node Dissection
9%
Initial Prostate Biopsy
9%
Rigid Ureteroscopy
9%
Enhanced Recovery Program
9%
Human Prostate Tissue
9%
Partial Nephrectomy
9%
Transitional Cell Carcinoma of the Urothelium
9%
Mild Hyperthermia
9%
Outcome Patterns
9%
Holmium Laser
9%
